Quantcast
Last updated on April 24, 2014 at 12:23 EDT

Latest Neuroactive steroid Stories

2013-01-07 08:29:26

BRANFORD, Conn., Jan. 7, 2013 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. Based in Branford, Connecticut, Marinus is the developer of the first-in-class, neuroactive steroid Ganaxolone. Marinus Pharmaceuticals--the leader in the development of...

2011-12-14 10:12:27

Neuroscience researchers from Tufts identify potential target for drug therapy for wide range of disorders associated with stress Neuroscience researchers from Tufts have demonstrated, for the first time, that the physiological response to stress depends on neurosteroids acting on specific receptors in the brain, and they have been able to block that response in mice. This breakthrough suggests that these critical receptors may be drug therapy targets for control of the stress-response...

2011-04-13 07:00:00

NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with...

2011-04-07 07:00:00

NEW HAVEN, Conn., April 7, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of...

2011-02-15 19:53:52

    * Alcohol dependence (AD) may develop through alcohol's effects on neural signaling.    * Researchers have found that neuroactive steroids may mediate some of the effects of alcohol on ÃŽ³-aminobutyric acid type A (GABAA) receptors.    * These findings suggest that genetic variations in neuroactive steroid-producing enzymes may be related to risk for AD. One of the ways in which alcohol dependence (AD) may develop is through...

2009-12-08 13:11:00

Findings with Newly Returning Veterans NASHVILLE, Tenn., Dec. 8 /PRNewswire-USNewswire/ -- Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) frequently experience high rates of PTSD along with symptoms of depression and pain. However, little is known about why these symptoms occur together or the most effective treatments that can be used to alleviate them. One approach that may yield new insights is to search for biomarkers -- indicators of a biological...

2ba75c16e48b3f9ea32f22b54d182cd01
2005-02-08 08:17:27

Study suggests over-the-counter hormone can ease symptoms HealthDay News -- Treatment with the over-the-counter hormonal therapy DHEA (dehydroepiandrosterone) may be effective in treating midlife-onset minor and major depression, according to a study in the February issue of the journal Archives of General Psychiatry. DHEA, an androgen hormone produced naturally by the adrenal gland, is also classified as a neurosteroid due to its effects on the brain. DHEA is also sold in supplement form in...